October 1, 2018

CHAIN features in a new explainer document on engineering biology from the UK Bioindustry Association (BIA) published today. Engineering Biology Explained discusses what these areas are all about, showcasing the important contributions made to these industries by UK bioscience companies and outlining the external environment required to ensure that these areas of innovation continue to benefit patients, […]

June 1, 2018

Ben Bradley, our Head of Partnerships and Licensing, is attending Gut-Brain Axis 2018, part of the Biotech Pharma Summit conference series in Paris September 6 & 7. This year’s event brings together leading scientists, physicians, and senior leaders to explore the brain and its engagement with the GI-nervous system axis in health and disease. Chief Executive Dr […]

March 26, 2018

UK biotech to manufacture novel medicines for Inflammatory Bowel Disease using spores of gut bacteria Three leading British biotechnology businesses have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines, targeting a range of clinical conditions through interaction with the human microbiome. The novel and highly innovative approach […]

February 28, 2018

CHAIN has been awarded £0.5M grant funding from Innovate UK, the UK’s Innovation agency, to expand its range of biotechnology products. Building on a successful synthetic biology program, the grants support further development of CHAIN’s proprietary Clostridium platform for therapeutic and specialty chemical applications. A two-year project will focus on the development of novel therapeutics […]

February 9, 2018

CHAIN plans to attend a record number of microbiome and biotech conferences over the next year to showcase our therapeutic platform and identify partners for the development of novel, targeted therapies. First up is the Spores Conference in April where our Technical Product Manager, Dr Daniela Heeg, will speak about CHAIN’s novel therapeutic delivery platform. […]

November 24, 2017

CHAIN are excited to announce the launch of our re-designed website. The new look features a sleek design optimised for mobile and tablet readers to showcase our novel technology platform and how microbiome therapy. In addition to our main site, we now have an e-shop for customers to purchase molecular biology tools and strains. Microbiome […]

July 25, 2017

CHAIN welcomes to its Board of Directors the recent appointment of Dr Mike McDonald and Peter McPartland as Non-Executive Directors. The appointments follow CHAIN’s successful seed investment round, led by Rainbow Seed Fund, earlier this year. Dr McDonald, a physician, brings 30 years of experience in US and European drug development. He has leadership and […]

August 18, 2016

CHAIN Biotechnology is proud to announce that it is a finalist in two competitions celebrating excellence in the fields of biotechnology and life sciences. CHAIN has made it to the final round of the OBN Awards for “Best Emerging UK Synthetic Biotech” and the Institute of Chemical Engineering (IChemE) Global Awards for “Best Business Start-Up”. […]

August 10, 2016

LONDON, UK, 10 AUGUST 2016 — CHAIN Biotechnology Ltd has successfully completed a 12-month research project entitled “Chiral Chemical Synthesis in Clostridia”. The research was supported by a grant from Innovate UK, the UK’s innovation agency. Specifically, CHAIN has demonstrated a new way to change the stereochemistry of intracellular metabolism in Clostridia bacteria, resulting in […]

June 10, 2016

June 11, 2016 – London, UK. CHAIN Biotechnology Ltd has won grant funding for two new research collaborations which advance CHAIN’s synthetic biology platform and microbial engineering capabilities. The first project – called PUFA (polyunsaturated fatty acids) – sees CHAIN partnering with the University of Nottingham. PUFA will use advances in synthetic biology to develop […]